QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-0.92%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-0.92%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-0.92%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-0.92%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
NASDAQ:LNTH

Lantheus - LNTH Stock Forecast, Price & News

$55.84
+1.19 (+2.18%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$55.00
$55.94
50-Day Range
$47.76
$62.08
52-Week Range
$23.51
$87.47
Volume
539,099 shs
Average Volume
940,912 shs
Market Capitalization
$3.84 billion
P/E Ratio
37.48
Dividend Yield
N/A
Price Target
$102.80

Lantheus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
84.1% Upside
$102.80 Price Target
Short Interest
Healthy
5.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.67
Upright™ Environmental Score
News Sentiment
0.59mentions of Lantheus in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$1.11 M Sold Last Quarter
Proj. Earnings Growth
11.05%
From $3.53 to $3.92 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.93 out of 5 stars

Medical Sector

55th out of 1,048 stocks

Diagnostic Substances Industry

1st out of 17 stocks


LNTH stock logo

About Lantheus (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
See More Headlines
Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Company Calendar

Last Earnings
11/03/2022
Today
1/26/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LNTH
Employees
612
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$102.80
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$91.00
Forecasted Upside/Downside
+84.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-71,280,000.00
Pretax Margin
20.21%

Debt

Sales & Book Value

Annual Sales
$425.21 million
Cash Flow
$1.31 per share
Book Value
$6.86 per share

Miscellaneous

Free Float
67,731,000
Market Cap
$3.84 billion
Optionable
Optionable
Beta
0.78

Key Executives

  • Ms. Mary Anne HeinoMs. Mary Anne Heino (Age 63)
    CEO, Pres & Director
    Comp: $2.15M
  • Mr. Robert J. Marshall Jr.Mr. Robert J. Marshall Jr. (Age 56)
    CFA, Chief Financial Officer
    Comp: $905.94k
  • Mr. Paul M. BlanchfieldMr. Paul M. Blanchfield (Age 42)
    Chief Operating Officer
    Comp: $734.54k
  • Mr. Daniel M. NiedzwieckiMr. Daniel M. Niedzwiecki (Age 46)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $627.1k
  • Mr. Etienne MontagutMr. Etienne Montagut (Age 48)
    Chief Bus. Officer
    Comp: $607.99k
  • Ms. Andrea SabensMs. Andrea Sabens (Age 44)
    Chief Accounting Officer
  • Ms. Dorothy Barr
    Sr. VP of Manufacturing & Technical Operations
  • Mr. Mark Richard Kinarney
    Sr. Director of Investor Relations
  • Ms. Linda S. Lennox (Age 57)
    VP of Corp. Communications & Chief of Staff
  • Melissa Downs
    Director of Corp. Communications













LNTH Stock - Frequently Asked Questions

Should I buy or sell Lantheus stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LNTH shares.
View LNTH analyst ratings
or view top-rated stocks.

What is Lantheus' stock price forecast for 2023?

5 brokers have issued 12 month target prices for Lantheus' shares. Their LNTH share price forecasts range from $91.00 to $120.00. On average, they predict the company's share price to reach $102.80 in the next twelve months. This suggests a possible upside of 84.1% from the stock's current price.
View analysts price targets for LNTH
or view top-rated stocks among Wall Street analysts.

How have LNTH shares performed in 2023?

Lantheus' stock was trading at $50.96 at the beginning of the year. Since then, LNTH stock has increased by 9.6% and is now trading at $55.84.
View the best growth stocks for 2023 here
.

Are investors shorting Lantheus?

Lantheus saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 3,450,000 shares, a drop of 5.5% from the December 31st total of 3,650,000 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is currently 3.1 days. Approximately 5.1% of the shares of the company are short sold.
View Lantheus' Short Interest
.

When is Lantheus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our LNTH earnings forecast
.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) released its quarterly earnings results on Thursday, November, 3rd. The medical equipment provider reported $0.90 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.15. The medical equipment provider earned $239.29 million during the quarter, compared to analysts' expectations of $228.52 million. Lantheus had a net margin of 13.35% and a trailing twelve-month return on equity of 37.77%.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus issued an update on its fourth quarter 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of $0.95-$0.98 for the period, compared to the consensus EPS estimate of $0.86. The company issued revenue guidance of $243.00 million-$247.00 million, compared to the consensus revenue estimate of $238.01 million.

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?
When did Lantheus IPO?

(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Reinhart Partners Inc. (0.84%), Congress Asset Management Co. MA (0.50%), Allspring Global Investments Holdings LLC (0.45%), Assenagon Asset Management S.A. (0.45%), Peregrine Capital Management LLC (0.39%) and Comerica Bank (0.30%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends
.

How do I buy shares of Lantheus?

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $55.84.

How much money does Lantheus make?

Lantheus (NASDAQ:LNTH) has a market capitalization of $3.84 billion and generates $425.21 million in revenue each year. The medical equipment provider earns $-71,280,000.00 in net income (profit) each year or $1.49 on an earnings per share basis.

How many employees does Lantheus have?

The company employs 612 workers across the globe.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860.

This page (NASDAQ:LNTH) was last updated on 1/26/2023 by MarketBeat.com Staff